The Readout LOUD
Coverage of The Readout LOUD in the Nexus archive.
- Whistleblower takes on health insurance and FDA commissioner candidates
A whistleblower challenges an insurance contractor over high family health insurance costs, while potential candidates for the new FDA commissioner are discussed on 'The Readout LOUD' podcast. The episode explores rising health insurance prices and regulatory leadership changes.
- The mysterious case of Eli Lilly’s obesity drug
Eli Lilly's obesity drug retatrutide is being made available to one individual through the FDA's 'compassionate use' program. The article discusses this development alongside broader questions about drugmaker acquisitions and the investment potential of hair loss drugs, as covered in a podcast episode.
- An obesity drug deep-dive, and peptides move mainstream
The article discusses new obesity medications in development, a company that recently set IPO records, and potential FDA changes regarding access to experimental peptides. The focus is on advancements in obesity treatments and biotech industry developments.
- What RevMed’s pancreatic cancer drug meant for one patient
Revolution Medicines' pancreatic cancer drug, daraxonrasib, received a standing ovation from oncologists during a data presentation. The article also addresses the poor performance of biotech stocks this week and discusses other topics on 'The Readout LOUD' podcast.
- Guarding biotech from China and big bets in longevity
STAT's Breakthrough Summit West brought together leaders in healthcare and science to discuss biotech developments. Key topics included BridgeBio's research publication concerns and Retro Biosciences' progress toward clinical trials, with focus on AI's role in drug development.